Welcome to CDC Stacks | Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States - 30012 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States
Filetype[PDF - 331.46 KB]


Details:
  • Pubmed ID:
    24753070
  • Pubmed Central ID:
    PMC4069221
  • Funding:
    1U58 DP000807-01/DP/NCCDPHP CDC HHS/United States
    1US58/DP0039311-01/DP/NCCDPHP CDC HHS/United States
    5U58DP000812-03/DP/NCCDPHP CDC HHS/United States
    5U58DP000824-04/DP/NCCDPHP CDC HHS/United States
    5U58DP003875-01/DP/NCCDPHP CDC HHS/United States
    DP000805-04/DP/NCCDPHP CDC HHS/United States
    HHSN261201000024C/CA/NCI NIH HHS/United States
    HHSN261201000026C/CA/NCI NIH HHS/United States
    HHSN261201000027C/CA/NCI NIH HHS/United States
    HHSN261201000032C/CA/NCI NIH HHS/United States
    HHSN261201000034C/CA/NCI NIH HHS/United States
    HHSN261201000035C/CA/NCI NIH HHS/United States
    HHSN261201000036C/CA/NCI NIH HHS/United States
    HHSN261201000037C/CA/NCI NIH HHS/United States
    N01-PC-20100-027./PC/NCI NIH HHS/United States
    N01-PC-35137/PC/NCI NIH HHS/United States
    N01-PC-35139/PC/NCI NIH HHS/United States
    N01-PC-35142/PC/NCI NIH HHS/United States
    N01-PC-35143/PC/NCI NIH HHS/United States
    P30 CA086862/CA/NCI NIH HHS/United States
    U58 DP000848-04/DP/NCCDPHP CDC HHS/United States
    U58DP000832/DP/NCCDPHP CDC HHS/United States
    U58DP0038789/DP/NCCDPHP CDC HHS/United States
    Intramural NIH HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Non-Hodgkin lymphoma arising in the context of immunosuppression is an important adverse outcome after solid organ transplantation. Diffuse large B-cell lymphoma (DLBCL) is the most commonly diagnosed subtype of post-transplantation non-Hodgkin lymphoma, but few studies of transplant recipients have examined subtype-specific risks. Therefore, we examined DLBCL risk in the Transplant Cancer Match Study, including registry-based cancer ascertainment among 96,615 solid organ transplants performed from 2000 to 2008. We determined standardized incidence ratios (SIRs) and 95% confidence intervals comparing DLBCL risk in transplant recipients with that in the general population, and used multivariable Poisson regression models to assess the impact of potential risk factors. We identified 321 incident cases of DLBCL, over 12 times more than expected based on general population rates (SIR = 12.6, 95% confidence interval = 11.2-14.0). SIRs were highest in young recipients and those receiving a lung or pancreas/kidney-pancreas transplant, and were greatly elevated for extranodal DLBCLs at the site of the transplantation compared with other sites. DLBCL risk was highest in the first year following transplantation, and SIRs for early-onset DLBCL risk were elevated in association with Epstein-Barr virus-negative serostatus and use of polyclonal antibody induction therapy. In conclusion, associations between recipient and transplant factors and post-transplantation DLBCL risk suggest a complicated interrelationship among multiple risk factors and timing of disease.